56776-01-3
基本信息
盐酸妥布特罗
盐酸妥洛特罗
盐酸妥布托罗
盐酸妥布特
(+/-)-2-氯-2-[(叔丁基氨基)甲基]苯甲醇盐酸盐
TULOBUTEROL HCL
TULOBUTEROL HYDROCHLORIDE
1-(o-chlorophenyl)-2-tert-butylaminoethanolhydrochloride
2-chloro-alpha-(((1,1-dimethylethyl)amino)methyl)-benzenemethanohydrochl
alpha-((tert-butylamino)methyl)-o-chloro-benzylalcohohydrochloride
alpha-(tert-butylamino)methyl-2-chloro-benzylalcohohydrochloride
alpha-(tert-butylamino)methyl-2-chlorobenzylalcoholhydrochloride
c78
chlobamolhydrochloride
lobuterol
o-chloro-alpha-((tert-butylamino)methyl)benzylalcoholhydrochloride
TULOBUTEROL HG 99%
TULOBUTEROL HG
Atenos
Benzenemethanol, 2-chloro-a-[[(1,1-dimethylethyl)amino]methyl]-, hydrochloride (9CI)
Berachin
Brelomax
Bremax
Chlibamol
物理化学性质
| 熔点 | 159-163℃ |
| 储存条件 | 2-8°C |
| 溶解度 | 可溶于DMSO（少许）、甲醇（少许） |
| 形态 | neat |
| 颜色 | 白色 |
| 水溶解性 | Soluble in methanol or water. |
| 敏感性 | 吸湿性 |
| Merck | 14,9811 |
| InChIKey | RSLNRVYIRDVHLY-UHFFFAOYSA-N |
| CAS 数据库 | 56776-01-3(CAS DataBase Reference) |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302 |
| 防范说明 | P264-P270-P301+P312-P501 |
| 危险品标志 | Xn |
| 危险类别码 | R22 |
| WGK Germany | 3 |
| RTECS号 | DN8785000 |
| 海关编码 | 2922.19.7000 |
56776-01-3(安全特性,毒性,储运)
知名试剂公司产品信息
盐酸妥布特罗价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/01/25 | HY-W011733 | 盐酸妥布特罗 Tulobuterol hydrochloride | 56776-01-3 | 50mg | 600元 |
| 2024/01/25 | HY-W011733 | 盐酸妥布特罗 Tulobuterol hydrochloride | 56776-01-3 | 10mM * 1mLin DMSO | 660元 |
| 2024/01/25 | HY-W011733 | 盐酸妥布特罗 Tulobuterol hydrochloride | 56776-01-3 | 100mg | 800元 |
常见问题列表
β2-adrenoceptor
Tulobuterol (0.1 μM; 24 hours or 72 hours; human tracheal epithelial cells) treatment decreases the RV14 RNA levels at 1 day and at 3 days after infection. The concentrations of sICAM-1 in the supernatants of the cells treated with tulobutero are significantly lower than those in the cells treated with vehicle before RV14 infection. Treatment with tulobuterol reduces the number of acidic endosomes with green fluorescence in the cells and the fluorescence intensity of acidic endosomes in the cells. Also reduces the RV14 infection-induced secretion of IL-1β, IL-6, and IL-8. Tulobuterol treatment produces a small but significant reduction in the amount of p50, p65, and c-Rel of NF-κB induced by RV14 infection.
RT-PCR
| Cell Line: | Human tracheal epithelial cells infected with RV14 |
| Concentration: | 0.1 μM |
| Incubation Time: | 24 hours or 72 hours |
| Result: | Decreased the RV14 RNA levels at 1 day and at 3 days after infection. The concentrations of sICAM-1 in the supernatants of the cells were significantly lower. Reduced the number of acidic endosomes with green fluorescence in the cells and the fluorescence intensity of acidic endosomes in the cells. Also reduced the RV14 infection-induced secretion of IL-1β, IL-6, and IL-8. And produced a small but significant reduction in the amount of p50, p65, and c-Rel of NF-κB induced by RV14 infection. |
In vivo effect of Tulobuterol is examined the on the contractility of diaphragm muscles prepared from mice (BALBs/c mice; 21.7 ± 0.2 g) treated with Endotoxin. Contractile parameters of force-frequency curves and twitch kinetics using untreated or treated diaphragm muscles at 0 (E0) and 4 (E4) hours after E. coli endotoxin (20 mg/kg) administration are measured. E0 and E4 diaphragm muscles are analyzed at 0, 12, and 24 h after transdermal Tulobuterol treatment. The force-frequency curves of E0 and E4 diaphragm muscles at three time points are not significantly changed each other, indicating that Tulobuterol patch restores the muscle contractility. Thus, diaphragm muscle contractility is maintained during 4 h of endotoxin administration with Tulobuterol patch for over 24 h.